Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On April 15, 2013, the Administrators of the Deferred Investment Award Programme notified the Company of increases in notional interests in Ordinary Shares for specific individuals. These increases resulted from the re-investment of the dividend paid to shareholders on April 11, 2013, at a price of 1,556.75 pence per Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 15, 2013 (Notification date); April 11, 2013 (Dividend payment date).
- Share Price: 1,556.75 pence per Share for the reinvestment.
- Participants: Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Type: Increase in notional interests via dividend reinvestment.